Understanding the Challenge
Cancer cases are increasing, especially among younger adults. However, many new drug candidates fail during clinical trials. Fanny Jaulin, a French entrepreneur, believes that the design of these trials is a key issue. She asserts that a drug’s failure in trials does not necessarily reflect its quality. This highlights the urgent need for improved trial methods, particularly for cancers that have seen little progress in treatment options over the years.
Key Details About Orakl Oncology
- Orakl Oncology, founded in 2023, uses AI to enhance clinical trials.
- The startup combines data and biology, setting it apart from competitors.
- Their approach involves creating hybrid avatars that represent real patients.
- Orakl focuses initially on colorectal and pancreatic cancers, with plans for two products: O-Predict and O-Validate.
The Bigger Picture
The rise in cancer incidence and the stagnation in drug development indicate a pressing need for innovation in this field. Orakl’s work aims to streamline the drug discovery process, making it more efficient and effective. By focusing on precision medicine and leveraging advanced AI techniques, Jaulin hopes to ensure that more effective treatments reach patients in need. The funding received will help build a commercial team, enhancing their capacity to deliver these solutions to the market.
